Verona Pharma plc (NASDAQ:VRNA – Get Free Report) was the target of a significant increase in short interest in August. As of August 15th, there was short interest totalling 10,700,000 shares, an increase of 21.0% from the July 31st total of 8,840,000 shares. Based on an average trading volume of 1,480,000 shares, the short-interest ratio is presently 7.2 days.
Analyst Upgrades and Downgrades
Several research analysts have recently weighed in on the stock. HC Wainwright lifted their target price on shares of Verona Pharma from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th. Truist Financial lifted their target price on shares of Verona Pharma from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, June 28th. Finally, Canaccord Genuity Group lifted their target price on shares of Verona Pharma from $35.00 to $37.00 and gave the stock a “buy” rating in a research report on Monday, July 22nd. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $36.00.
Read Our Latest Stock Report on VRNA
Institutional Trading of Verona Pharma
Verona Pharma Stock Performance
VRNA stock opened at $27.48 on Friday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 8.61 and a current ratio of 8.61. The stock has a market cap of $2.20 billion, a P/E ratio of -35.69 and a beta of 0.44. The firm has a 50 day simple moving average of $21.84 and a 200 day simple moving average of $17.56. Verona Pharma has a 52 week low of $11.39 and a 52 week high of $28.83.
Verona Pharma (NASDAQ:VRNA – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.53). During the same period last year, the business posted ($0.11) EPS. Research analysts anticipate that Verona Pharma will post -2.07 earnings per share for the current fiscal year.
Verona Pharma Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading
- Five stocks we like better than Verona Pharma
- Top Biotech Stocks: Exploring Innovation Opportunities
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Investing in Commodities: What Are They? How to Invest in Them
- Why Dell Can Continue Winning in AI and Beyond
- Dividend Capture Strategy: What You Need to Know
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.